Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.



<ul>
<li>Seaport Global analyst Jay Goldberg initiated coverage on Applied Materials Inc (NASDAQ:AMAT) with a Buy rating and announced a price target of $500. Applied Materials shares traded at $412.58 on Tuesday. See how other analysts view this stock.</li>



<li>Citizens analyst Jonathan Wolleben initiated coverage on Biomea Fusion Inc (NASDAQ:BMEA) with a Market Outperform rating and announced a price target of $9. Biomea Fusion shares traded at $1.49 on Tuesday. See how other analysts view this stock.</li>



<li>Guggenheim analyst Seamus Fernandez initiated coverage on Aclaris Therapeutics Inc (NASDAQ:ACRS) with a Buy rating and announced a price target of $12. Aclaris Therapeutics shares traded at $4.68 on Tuesday. See how other analysts view this stock.</li>



<li>UBS analyst Alex Stansbury initiated coverage on Kaiser Aluminum Corp (NASDAQ:KALU) with a Neutral rating and announced a price target of $176. Kaiser Aluminum shares traded at $177.15 on Tuesday. See how other analysts view this stock.</li>



<li>Wedbush analyst Laura Chico initiated coverage on Sionna Therapeutics Inc (NASDAQ:SION) with an Outperform rating and announced a price target of $53. Sionna Therapeutics shares traded at $40.94 on Tuesday. See how other analysts view this stock.</li>
</ul>



Considering buying AMAT stock? Here’s what analysts think: 



<figure class="wp-block-image size-large is-resized"></figure>



Photo via Shutterstock

ACRS

KALU

SION

AMAT

BMEA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Seaport Global's Jay Goldberg rated Applied Materials (AMAT) as Buy with a $500 target. Citizens' Jonathan Wolleben rated Biomea Fusion (BMEA) as Market Outperform with a $9 target. Guggenheim's Seamus Fernandez rated Aclaris Therapeutics (ACRS) as Buy with a $12 target. UBS's Alex Stansbury rated Kaiser Aluminum (KALU) as Neutral with a $176 target. Wedbush's Laura Chico rated Sionna Therapeutics (SION) as Outperform with a $53 target.

benzinga_article

Aclaris Therap

Kaiser Aluminum

Sionna Therapeutics

Applied Materials

Biomea Fusion

Shutterstock

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday